Amundi ESTOXX50 Dly -1X Inv UCITS -A 

€7.32
596
+€0.05+0.7% Today

Statistics

Day High
7.32
Day Low
7.27
52W High
8.28
52W Low
6.92
Volume
-
Avg. Volume
-
Mkt Cap
10.86B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.59
0.63
0.67
0.71
Expected EPS
0.71058846232
Actual EPS
N/A

Financials

14.44%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
34.53BRevenue
4.99BNet Income

Analyst Ratings

69.45Average Price Target
The highest estimate is 89.54.
From 19 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSK7.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Show more...
CEO
Mr. Michael F. Mahoney
Employees
59000
Country
United States
ISIN
FR0010424135
WKN
000A0MNT8

Listings

0 Comments

Share your thoughts

FAQ

What is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price today?
The current price of LSK7.F is €7.32 EUR — it has increased by +0.7% in the past 24 hours. Watch Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price performance more closely on the chart.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amundi ESTOXX50 Dly -1X Inv UCITS -A stocks are traded under the ticker LSK7.F.
Is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price growing?
LSK7.F stock has risen by +2.28% compared to the previous week, the month change is a -5.99% fall, over the last year Amundi ESTOXX50 Dly -1X Inv UCITS -A has showed a -11.34% decrease.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A market cap?
Today Amundi ESTOXX50 Dly -1X Inv UCITS -A has the market capitalization of 10.86B
When is the next Amundi ESTOXX50 Dly -1X Inv UCITS -A earnings date?
Amundi ESTOXX50 Dly -1X Inv UCITS -A is going to release the next earnings report on July 29, 2026.
What were Amundi ESTOXX50 Dly -1X Inv UCITS -A earnings last quarter?
LSK7.F earnings for the last quarter are 0.68 EUR per share, whereas the estimation was 0.67 EUR resulting in a +1.51% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A revenue for the last year?
Amundi ESTOXX50 Dly -1X Inv UCITS -A revenue for the last year amounts to 34.53B EUR.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A net income for the last year?
LSK7.F net income for the last year is 4.99B EUR.
How many employees does Amundi ESTOXX50 Dly -1X Inv UCITS -A have?
As of April 29, 2026, the company has 59,000 employees.
In which sector is Amundi ESTOXX50 Dly -1X Inv UCITS -A located?
Amundi ESTOXX50 Dly -1X Inv UCITS -A operates in the Health & Wellness sector.
When did Amundi ESTOXX50 Dly -1X Inv UCITS -A complete a stock split?
Amundi ESTOXX50 Dly -1X Inv UCITS -A has not had any recent stock splits.
Where is Amundi ESTOXX50 Dly -1X Inv UCITS -A headquartered?
Amundi ESTOXX50 Dly -1X Inv UCITS -A is headquartered in Marlborough, United States.